

09/ 918,039

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

09/ 918,039

FILE 'HOME' ENTERED AT 14:39:27 ON 19 SEP 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:39:33 ON 19 SEP 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2002 HIGHEST RN 452896-77-4

DICTIONARY FILE UPDATES: 18 SEP 2002 HIGHEST RN 452896-77-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>






Uploading 09918039.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

09/ 918,039

=> s l1

SAMPLE SEARCH INITIATED 14:40:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 14:40:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> s pyrrolo and pyridin

159029 PYRROLO

715262 PYRIDIN

L4 11495 PYRROLO AND PYRIDIN

=>

Uploading 09918039.str

L5 STRUCTURE UPLOADED

=> s l5

SAMPLE SEARCH INITIATED 14:41:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 725 TO ITERATE

100.0% PROCESSED 725 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 12885 TO 16115
PROJECTED ANSWERS: 3421 TO 5179

L6 50 SEA SSS SAM L5

=> d l5

L5 HAS NO ANSWERS

L5 STR



G1 C,N

09/ 918,039

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 14:39:27 ON 19 SEP 2002)

FILE 'REGISTRY' ENTERED AT 14:39:33 ON 19 SEP 2002

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FUL
L4 11495 S PYRROLO AND PYRIDIN
L5 STRUCTURE UPLOADED
L6 50 S L5

=> s l5 sub=l4 ful

FULL SUBSET SEARCH INITIATED 14:42:03 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.01

L7 64 SEA SUB=L4 SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	289.32	289.53

FILE 'CAPLUS' ENTERED AT 14:42:10 ON 19 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2002 VOL 137 ISS 12
FILE LAST UPDATED: 18 Sep 2002 (20020918/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l7

L8 7 L7

=> d l8 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

09/ 918,039

L8 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:630893 CAPLUS

DOCUMENT NUMBER: 135:195505

TITLE: Preparation of azaheterocyclic sulfonamides as factor Xa inhibitors

INVENTOR(S): Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong; Levell, Julian

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: U.S., 96 pp., Cont.-in-part of U.S. Ser. No. 90,492.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 6281227 B1 20010828 US 1999-453307 19991202

WO 9825611 A1 19980618 WO 1997-US22406 19971203

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

WO 9962904 A1 19991209 WO 1999-US12312 19990603

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001039759 A2 20010607 WO 2000-EP11577 20001121

WO 2001039759 A3 20020117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002013310 A1 20020131 US 2001-918039 20010730

PRIORITY APPLN. INFO.: US 1996-33159P P 19961213

WO 1997-US22406 A2 19971203

US 1998-90492 A2 19980603


WO 1999-US12312 A2 19990603

US 1999-453307 A 19991202

OTHER SOURCE(S): MARPAT 135:195505

GI

S.I.E.
Applicants



AB Title compds. [I; X = (CHR₃)_m; R = (un)substituted heteroaryl; R₁, R₂ = H, (un)substituted alkyl, alkenyl, aralkyl; R₃ = H, OH, (un)substituted alkyl, aryl, heteroaryl; R₄ = H, (un)substituted alkyl, aryl, aralkyl; R₅, R₆ = H; R₅R₆ = O; R₇, R₈ = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl; R₇R₈ = O; R₃R₇ = alkylene; m = 0-3] were prepd. Thus, title compd. II was prepd. from 3-acetamido-4-methylbenzaldehyde, malonic acid, and 7-methoxy-2-naphthalenesulfonyl chloride in 10 steps. II had a K_i of 80 nM for inhibition of factor Xa.


IT 209285-80-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 209285-80-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209286-49-7P 209286-51-1P 209286-82-8P
209286-84-0P 209286-89-5P 209286-91-9P
209286-92-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)


RN 209286-49-7 CAPLUS

CN Carbamic acid, [(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-

09/ 918,039

pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209286-51-1 CAPLUS


CN 2-Pyrrolidinone, 3-amino-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 209286-50-0

CMF C13 H16 N4 O


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 209286-82-8 CAPLUS

CN Carbamic acid, [(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 918,039

RN 209286-84-0 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209286-89-5 CAPLUS

CN Carbamic acid, [(3S)-1-[[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209286-91-9 CAPLUS

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 209286-92-0 CAPLUS

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[(5-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209285-47-2P 209285-74-5P 209285-75-6P
209285-77-8P 209285-81-4P 209285-82-5P
209285-83-6P 209285-84-7P 209285-85-8P
251936-19-3P 251936-23-9P 251937-72-1P
251937-73-2P 251937-74-3P 251937-75-4P
251937-76-5P 251937-77-6P 251937-78-7P
251937-79-8P 251937-80-1P 251937-81-2P
251937-82-3P 251937-83-4P 251937-84-5P
251937-85-6P 251937-86-7P 251937-87-8P
251937-88-9P 251937-89-0P 251937-90-3P
251937-91-4P 251937-92-5P 251937-93-6P
251937-94-7P 251937-95-8P 251937-96-9P
251937-97-0P 251937-98-1P 251937-99-2P
251938-00-8P 251938-01-9P 251938-02-0P
251938-03-1P 251938-04-2P 251938-05-3P
251938-06-4P 251938-07-5P 251938-08-6P
251938-35-9P 251938-38-2P 251938-39-3P
251938-46-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prep. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 209285-47-2 CAPLUS

CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 209285-46-1

CMF C24 H24 N4 O4 S

Absolute stereochemistry.


09/ 918,039



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 209285-74-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-75-6 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-yl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 918,039




RN 209285-77-8 CAPLUS
CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 209285-76-7
CMF C23 H22 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 209285-81-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

09/ 918,039


CRN 209285-80-3
CMF C20 H17 Cl N4 O3 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 209285-82-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/ 918,039

RN 209285-83-6 CAPLUS


CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-82-5

CMF C20 H17 Cl N4 O3 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 209285-84-7 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 918,039




RN 209285-85-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-84-7
CMF C19 H17 N5 O3 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


09/ 918,039



RN 251936-19-3 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251936-23-9 CAPLUS

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 251937-72-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 918,039

RN 251937-73-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-74-3 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-75-4 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-76-5 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-77-6 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-78-7 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-79-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-80-1 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-81-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-82-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-83-4 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 918,039

RN 251937-84-5 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-85-6 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-86-7 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-87-8 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-88-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-89-0 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazoly)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-90-3 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-91-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-92-5 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-93-6 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-94-7 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-95-8 CAPLUS

09/ 918,039

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-96-9 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-97-0 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-98-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-99-2 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-00-8 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251938-01-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-02-0 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-03-1 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-04-2 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-05-3 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-06-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-07-5 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-08-6 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-35-9 CAPLUS

CN 2-Pyrrolidinone, 1-[(4-amino-7-quinazolinyl)methyl]-3-[(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-38-2 CAPLUS

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3R)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 251938-39-3 CAPLUS

CN Glycine, N-[[2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3R)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

09/ 918,039




RN 251938-46-2 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3R)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 251938-45-1
CMF C19 H17 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:416755 CAPLUS

09/ 918,039

DOCUMENT NUMBER: 135:46082
TITLE: Preparation of N-(oxopyrrolidinyl)naphthalenesulfonamides and analogs as factor Xa inhibitors
INVENTOR(S): Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong; Levell, Julian
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001039759	A2	20010607	WO 2000-EP11577	20001121
WO 2001039759	A3	20020117		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6281227	B1	20010828	US 1999-453307	19991202
PRIORITY APPLN. INFO.:				
			US 1999-453307	A 19991202
			US 1996-33159P	P 19961213
			WO 1997-US22406	A2 19971203
			US 1998-90492	A2 19980603
			WO 1999-US12312	A2 19990603
OTHER SOURCE(S): MARPAT 135:46082				
GI				



I

AB Title compds. [(un)substituted I; R = N-contg. heteroaryl; R₁ = H, (acyl)alkyl, (hetero)arylalkyl, etc.; R₂ = H, (hetero)arylalkyl, carbamoylalkyl, etc.; Z = (NH- or NHCO-interrupted or -terminated) alkylene; Z₁ = (CH₂)₀₋₃] were prepd. Thus, I (R₁ = H, Z₁ = CH₂) (II; R = H, R₂ = CO₂Me₃, Z = bond) was N-alkylated by 7-bromomethyl-1-chloroisoquinoline (prepn. each given) and the deprotected product N-acylated by 7-methoxynaphthalene-2-sulfonyl chloride (prepn. given) to give, in 2 addnl. steps, II (R = 1-amino-7-isoquinolyl, R₂ = 7-methoxynaphthalene-2-sulfonyl, Z = CH₂). Data for biol. activity of I were given.

IT 209285-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(oxopyrrolidinyl)naphthalenesulfonamides and analogs as factor Xa inhibitors)

09/ 918,039

RN 209285-47-2 CAPLUS


CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-46-1

CMF C24 H24 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 209286-49-7P 209286-50-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-(oxopyrrolidinyl)naphthalenesulfonamides and analogs as factor Xa inhibitors)

RN 209286-49-7 CAPLUS

CN Carbamic acid, [(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209286-50-0 CAPLUS

CN 2-Pyrrolidinone, 3-amino-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:543073 CAPLUS

DOCUMENT NUMBER: 133:261091

TITLE: Crystal Structures of Human Factor Xa Complexed with Potent Inhibitors

AUTHOR(S): Maignan, Sebastien; Guilloteau, Jean-Pierre; Pouzieux, Stephanie; Choi-Sledeski, Yong Mi; Becker, Michael R.; Klein, Scott I.; Ewing, William R.; Pauls, Henry W.; Spada, Alfred P.; Mikol, Vincent

CORPORATE SOURCE: Department of Structural Biology, Aventis Pharma, Vitry/Seine, F-94403, Fr.

SOURCE: Journal of Medicinal Chemistry (2000), 43(17), 3226-3232

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Involved in the coagulation cascade, factor Xa (FXa) is a serine protease which has received great interest as a potential target for the development of new antithrombotics. Although there is a great wealth of structural data on thrombin complexes, few structures of ligand/FXa complexes have been reported, presumably because of the difficulty in growing crystals. Reproducible crystn. conditions for human des-Gla1-45 coagulation FXa have been found. This has led to an improvement in the diffraction quality of the crystals (about 2.1 .ANG.) when compared to the previously reported forms (2.3-2.8 .ANG.) thus providing a suitable platform for a structure-based drug design approach. A series of crystal structures of noncovalent inhibitors complexed with FXa have been detd., three of which are presented herein. These include compds. contg. the benzamidine moiety and surrogates of the basic group. The benzamidine-contg. compd. binds in a canonical fashion typical of synthetic serine protease inhibitors. On the contrary, mols. that contain surrogates of the benzamidine group do not make direct hydrogen-bonding interactions with the carboxylate of Asp189 at the bottom of the S1 pocket. The structural data provide a likely explanation for the specificity of these inhibitors and a great aid in the design of bioavailable potent FXa inhibitors.

IT 209285-84-7, RPR 208707

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)


(crystal structures of human factor Xa complexed with potent inhibitors)

RN 209285-84-7 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

late
→



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:379659 CAPLUS

DOCUMENT NUMBER: 133:144473

TITLE: Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors

AUTHOR(S): Gong, Yong; Becker, Michael; Choi-Sledeski, Yong Mi; Davis, Roderick S.; Salvino, Joseph M.; Chu, Valeria; Brown, Karen D.; Pauls, Henry W.

CORPORATE SOURCE: Department of Medicinal Chemistry, Rhone-Poulenc Rorer, Collegeville, PA, 19426, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(10), 1033-1036

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.


DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 133:144473

GI

Case



I



II

AB A focused library (4.times.14) prepd. from 4-aminopyridine and 4-, 5-, and 6-azaindole templates was synthesized using 14 polymer-supported 4-amido-2,3,5,6-tetrafluorophenyl (TFP) sulfonate esters and heteroaryl-methyl-substituted arylsulfonamino pyrrolidinones such as I to give a library of factor Xa inhibitors such as II. Several compds. were identified as factor Xa inhibitors (IC50.ltoreq.0.1 .mu.M) helping to

establish the SAR among these four series of azarene pyrrolidinones.
E.g., factor Xa was inhibited by II with a K_i of 15 nM.

IT 209285-75-6P 209285-80-3P 209285-82-5P
209285-84-7P 251936-19-3P 251937-72-1P
251937-73-2P 251937-74-3P 251937-75-4P
251937-76-5P 251937-77-6P 251937-78-7P
251937-79-8P 251937-80-1P 251937-81-2P
251937-82-3P 251937-83-4P 251937-84-5P
251937-85-6P 251937-86-7P 251937-87-8P
251937-88-9P 251937-89-0P 251937-90-3P
251937-91-4P 251937-92-5P 251937-93-6P
251937-94-7P 251937-95-8P 251937-96-9P
251937-97-0P 251937-98-1P 251937-99-2P
251938-00-8P 251938-01-9P 251938-02-0P
251938-03-1P 251938-04-2P 251938-05-3P
251938-06-4P 251938-07-5P 251938-08-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(solid-phase prepn. of a library of heteroarylmethyl arylsulfonylamino pyrrolidinones as factor Xa inhibitors)

RN 209285-75-6 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-80-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 209285-82-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-84-7 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251936-19-3 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-72-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-73-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-74-3 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-75-4 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-76-5 CAPLUS

09/ 918,039

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-77-6 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-78-7 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-79-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-80-1 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-81-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-82-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-83-4 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-84-5 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-85-6 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-86-7 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-87-8 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-88-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-89-0 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-90-3 CAPLUS

09/ 918,039

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-91-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-92-5 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-93-6 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-94-7 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-95-8 CAPLUS

09/ 918,039

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-96-9 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-97-0 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-98-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-99-2 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-00-8 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251938-01-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-02-0 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-03-1 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-04-2 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-05-3 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-06-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-07-5 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-08-6 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:819359 CAPLUS

DOCUMENT NUMBER: 132:64065

TITLE: Preparation of fluorobenzoylated resins as solid phase synthesis supports

INVENTOR(S): Salvino, Joseph M.; Groneberg, Robert D.; Airey, John E.; Poli, Gregory B.; McGeehan, Gerard M.; Labaudiniere, Richard F.; Clerc, Francois-frederic; Bezard, Daniel Noel Andre

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967228	A1	19991229	WO 1999-US14252	19990623
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9947128	A1	20000110	AU 1999-47128	19990623
BR 9911487	A	20010320	BR 1999-11487	19990623
EP 1089988	A1	20010411	EP 1999-930628	19990623
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO			
JP 2002518555	T2	20020625	JP 2000-555882	19990623
NO 2000006662	A	20001227	NO 2000-6662	20001227
PRIORITY APPLN. INFO.:			US 1998-90558P	P 19980624
			WO 1999-US14252	W 19990623

OTHER SOURCE(S): CASREACT 132:64065

GI



AB Title resins [I; R = resin; R1-R3 = H or ring system substituent (sic); R4 = F, OH, alkanoyl- or aroyloxy, SO₃H, etc.; Z = Z1SO₂, Z1NHSO₂, Z1CH₂CO, Z1Z₂, etc.; Z1 = bond, (un)substituted phenylene, -alkylene, etc.; Z2 = (un)substituted phenylene] were prepd. The F atom ortho to the loading site permits the abs. loading of the resin to be detd. using ¹⁹F NMR.

IT 209285-75-6P 209285-80-3P 209285-82-5P

209285-84-7P 251936-19-3P 251937-72-1P

251937-73-2P 251937-74-3P 251937-75-4P

251937-76-5P 251937-77-6P 251937-78-7P

251937-79-8P 251937-80-1P 251937-81-2P

251937-82-3P 251937-83-4P 251937-84-5P

251937-85-6P 251937-86-7P 251937-87-8P

251937-88-9P 251937-89-0P 251937-90-3P

251937-91-4P 251937-92-5P 251937-93-6P

251937-94-7P 251937-95-8P 251937-96-9P

251937-97-0P 251937-98-1P 251937-99-2P

251938-00-8P 251938-01-9P 251938-02-0P

251938-03-1P 251938-04-2P 251938-05-3P

251938-06-4P 251938-07-5P 251938-08-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of fluorobenzoylated resins as solid phase synthesis supports)

RN 209285-75-6 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-80-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 209285-82-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-84-7 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251936-19-3 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-72-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-73-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-74-3 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-75-4 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-76-5 CAPLUS

09/ 918,039

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-77-6 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-78-7 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-79-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-80-1 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-81-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-82-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-83-4 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-84-5 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-85-6 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-86-7 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-87-8 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-88-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-89-0 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-90-3 CAPLUS

09/ 918,039

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-91-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-92-5 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-93-6 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-94-7 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-95-8 CAPLUS

09/ 918,039

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-96-9 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-97-0 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-98-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-99-2 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-00-8 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251938-01-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-02-0 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-03-1 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-04-2 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-05-3 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-06-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-07-5 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-08-6 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:784099 CAPLUS

DOCUMENT NUMBER: 132:22881

TITLE: Sulfonic acid or sulfonylamino N-(heteroaralkyl)azaheterocyclic amides as inhibitors of factor Xa

INVENTOR(S): Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong; Levell, Julian

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 202 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962904	A1	19991209	WO 1999-US12312	19990603
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9943298	A1	19991220	AU 1999-43298	19990603
EP 1086099	A1	20010328	EP 1999-955266	19990603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
BR 9910899	A	20011009	BR 1999-10899	19990603
JP 2002517393	T2	20020618	JP 2000-552115	19990603
US 6281227	B1	20010828	US 1999-453307	19991202
NO 2000005912	A	20010131	NO 2000-5912	20001122
US 2002013310	A1	20020131	US 2001-918039	20010730
PRIORITY APPLN. INFO.:				
US 1998-90492 A2 19980603				
US 1996-33159P P 19961213				
WO 1997-US22406 A2 19971203				

applicants

OTHER SOURCE(S) :
GI

MARPAT 132:22881



AB Aza heterocycles I [X = (CHR₃)_m; R = (un)substituted heteroaryl; R₁, R₂ = H, (un)substituted alkyl, alkenyl, aralkyl; R₃ = H, OH, (un)substituted alkyl, aryl, heteroaryl; R₄ = H, (un)substituted alkyl, aryl, aralkyl; R₅, R₆ = H; R₅R₆ = O; R₇, R₈ = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl; R₇R₈ = O; R₃R₇ = alkylene; m = 0-3] were prepd. I are inhibitors of the activity of Factor Xa. Thus, the amide II was prepd. from 3-acetamido-4-methylbenzaldehyde, malonic acid, and 7-methoxy-2-naphthalenesulfonyl chloride in 10 steps. II had a K_i of 80 nM for inhibition of factor Xa.

IT 209285-80-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 209285-80-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209286-49-7P 209286-51-1P 209286-82-8P
209286-84-0P 209286-89-5P 209286-91-9P

09/ 918,039

209286-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 209286-49-7 CAPLUS

CN Carbamic acid, [(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209286-51-1 CAPLUS


CN 2-Pyrrolidinone, 3-amino-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-, (3S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 209286-50-0

CMF C13 H16 N4 O


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 209286-82-8 CAPLUS

CN Carbamic acid, [(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CCOC(=O)N[C@H]1CCN(C1)CC2=C(C=C3C=CC(=C3N)C=C2N(S(=O)(=O)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6Cl

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

O=C1N[C@H](C2=CC=C3C(=C2)S=C(C=C3)S(=O)(=O)N)S(=O)(=O)N1c4ccc(Cl)c5cnccc45

CN Carbamic acid, [(3S)-1-[[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


CCOC(=O)N[C@H]1SCCNC1Cc2cnc3cc(Cl)ccc3n2S(=O)(=O)c4ccccc4

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI)

09/ 918,039

(CA INDEX NAME)


Absolute stereochemistry.



RN 209286-92-0 CAPLUS

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[(5-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl)methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209285-47-2P 209285-74-5P 209285-75-6P
209285-77-8P 209285-81-4P 209285-82-5P
209285-83-6P 209285-84-7P 209285-85-8P
251936-19-3P 251936-23-9P 251937-72-1P
251937-73-2P 251937-74-3P 251937-75-4P
251937-76-5P 251937-77-6P 251937-78-7P
251937-79-8P 251937-80-1P 251937-81-2P
251937-82-3P 251937-83-4P 251937-84-5P
251937-85-6P 251937-86-7P 251937-87-8P
251937-88-9P 251937-89-0P 251937-90-3P
251937-91-4P 251937-92-5P 251937-93-6P
251937-94-7P 251937-95-8P 251937-96-9P
251937-97-0P 251937-98-1P 251937-99-2P
251938-00-8P 251938-01-9P 251938-02-0P
251938-03-1P 251938-04-2P 251938-05-3P
251938-06-4P 251938-07-5P 251938-08-6P
251938-35-9P 251938-38-2P 251938-39-3P
251938-46-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 209285-47-2 CAPLUS

CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 209285-46-1

CMF C24 H24 N4 O4 S

Absolute stereochemistry.


09/ 918,039



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 209285-74-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209285-75-6 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 918,039




RN 209285-77-8 CAPLUS
CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 209285-76-7
CMF C23 H22 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 209285-81-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

09/ 918,039


CRN 209285-80-3
CMF C20 H17 Cl N4 O3 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 209285-82-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/ 918,039

RN 209285-83-6 CAPLUS


CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-82-5

CMF C20 H17 Cl N4 O3 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 209285-84-7 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 918,039



RN 209285-85-8 CAPLUS


CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-84-7

CMF C19 H17 N5 O3 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2


09/ 918,039



RN 251936-19-3 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251936-23-9 CAPLUS

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 251937-72-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 918,039

RN 251937-73-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-74-3 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-75-4 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-76-5 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-77-6 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-78-7 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-79-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-80-1 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-81-2 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-82-3 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-83-4 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09/ 918,039


RN 251937-84-5 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



CN 2-Thiophenesulfonamide, N- [(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


09/ 918,039



RN 251937-87-8 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-88-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-89-0 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251937-90-3 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-91-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-92-5 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-93-6 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-94-7 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-95-8 CAPLUS

09/ 918,039

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-96-9 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251937-97-0 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251937-98-1 CAPLUS

CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251937-99-2 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-00-8 CAPLUS

CN 2-Thiophenesulfonamide, 5-(3-isoxazolyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

09/ 918,039


Absolute stereochemistry.



RN 251938-01-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-02-0 CAPLUS

CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-03-1 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-04-2 CAPLUS

CN Thieno[3,2-c]pyridine-2-sulfonamide, 4-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251938-05-3 CAPLUS

CN 2-Thiophenesulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-06-4 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-3-methyl-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-07-5 CAPLUS

CN Thieno[2,3-c]pyridine-2-sulfonamide, 7-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-08-6 CAPLUS

CN 1H-Benzimidazole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 251938-35-9 CAPLUS

CN 2-Pyrrolidinone, 1-[(4-amino-7-quinazolinyl)methyl]-3-[(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251938-38-2 CAPLUS

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3R)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 251938-39-3 CAPLUS

CN Glycine, N-[[2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3R)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

09/ 918,039




RN 251938-46-2 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3R)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 251938-45-1
CMF C19 H17 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:402310 CAPLUS

09/ 918,039

DOCUMENT NUMBER: 129:81744
TITLE: Preparation of sulfonic acid or sulfonylamino
N-(heteroaralkyl)-azaheterocyclylamide compounds as
inhibitors of factor Xa
INVENTOR(S): Choi-Sledeski, Yong Mi; Pauls, Henry W.; Barton,
Jeffrey N.; Ewing, William R.; Green, Daniel M.;
Becker, Michael R.; et al.
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA;
Choi-Sledeski, Yong Mi; Pauls, Henry W.; Barton,
Jeffrey N.; Ewing, William R.; Green, Daniel M.
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825611	A1	19980618	WO 1997-US22406	19971203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9855182	A1	19980703	AU 1998-55182	19971203
AU 726637	B2	20001116		
EP 944386	A1	19990929	EP 1997-951573	19971203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
CN 1244798	A	20000216	CN 1997-181387	19971203
BR 9713921	A	20000321	BR 1997-13921	19971203
JP 2001506630	T2	20010522	JP 1998-526844	19971203
ZA 9711207	A	19980720	ZA 1997-11207	19971212
NO 9902853	A	19990810	NO 1999-2853	19990611
KR 2000057528	A	20000925	KR 1999-705236	19990611
US 6281227	B1	20010828	US 1999-453307	19991202
US 2002013310	A1	20020131	US 2001-918039	20010730
PRIORITY APPLN. INFO.:				
			US 1996-33159P	P 19961213
			WO 1997-US22406	W 19971203
			US 1998-90492	A2 19980603
			WO 1999-US12312	A2 19990603
			US 1999-453307	A3 19991202
OTHER SOURCE(S):	MARPAT 129:81744			
GI				



AB The compds. of formula [I; Ar1 = a bicyclic heteroaryl contg. ≥ 1 N atom; Z = alkenyl; R1 = H, (un)substituted alkyl, aralkyl, or heteroalkyl, hydroxyalkyl, carboxy alkyl, carbamoylalkyl, aminoalkyl, etc.; R2 = R3S(O)p, R3R4NS(O)p; R3 = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkenyl, heteroaralkenyl; or R1 and R3 taken together with N(O)p or NS(O)pNR4 through which R1 and R3 are linked from a 5 to 7 membered (un)substituted heterocyclyl; wherein p = 1, 2; R4 = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; X1, X1a = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or X and X1a are taken together to form oxo; X3 = H, OH, (un)substituted alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; or X3 or one of X1 and X1a taken together form a 4 to 7 membered cycloalkyl; X5, X5a, X5b = H, (un)substituted NH2, HONH, alkoxyamino, NHNH2, (un)substituted OH, CONH2 or SO2NH2, halo, cyano, NO2, etc.; one of X5, X5a, and X5b = H, HO or (H, optionally substituted lower alkyl, hydroxy, alkoxy, or amino)NH that substitutes the distal ring of Ar1 at a position alpha to a nitrogen thereof] herein exhibit useful pharmacol. activity and accordingly are incorporated into pharmaceutical compns. and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compds. of formula I, compns. contg. compds. of formula I, and their use, which are for treating a patient suffering from, or subject to, physiol. condition (disorder) which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa. The physiol. disorder is venous vasculature, arterial vasculature, abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure assocd. with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication or bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post-coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathol. thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or

09/ 918,039

disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections and cancer. Thus, 3-(S)-amino-1-(6-amino-1-chloroisoquinolin-7-ylmethyl)pyrrolidin-2-one was coupled with 7-methoxynaphthalene-2-sulfonyl chloride followed by amination with ammonium acetate in PhOH at 115.degree. for 2 h gave the title compd., N-[N-(isoquinolinylmethyl)oxopyrrolidinyl]naphthalenesulfonamide (II.CF₃CO₂H). II.CF₃CO₂H in vitro inhibited factor Xa, thrombin, trypsin, tissue-plasminogen activator (t-PA), plasmin and activated protein C with K_i value of 80 nM.

IT 209285-47-2P 209285-74-5P 209285-75-6P
209285-77-8P 209285-81-4P 209285-83-6P
209285-85-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclamide compds. as inhibitors of factor Xa)

RN 209285-47-2 CAPLUS


CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-46-1

CMF C24 H24 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 209285-74-5 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 209285-75-6 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209285-77-8 CAPLUS

CN 2-Naphthalenesulfonamide, 7-methoxy-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 209285-76-7

CMF C23 H22 N4 O4 S

Absolute stereochemistry.


09/ 918,039



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 209285-81-4 · CAPLUS


CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-80-3

CMF C20 H17 Cl N4 O3 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

09/ 918,039




RN 209285-83-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 209285-82-5
CMF C20 H17 Cl N4 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 209285-85-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, N-[(3S)-2-oxo-1-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-3-pyrrolidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209285-84-7
CMF C19 H17 N5 O3 S2


Absolute stereochemistry.

09/ 918,039



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 209286-49-7P 209286-51-1P 209286-82-8P
209286-84-0P 209286-89-5P 209286-91-9P
209286-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. of sulfonic acid or sulfonylamino N-(heteroaralkyl)-
azaheterocyclamide compds. as inhibitors of factor Xa)

RN 209286-49-7 CAPLUS

CN Carbamic acid, [(3S)-2-oxo-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-3-
pyrrolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209286-51-1 CAPLUS

CN 2-Pyrrolidinone, 3-amino-1-[2-(1H-pyrrolo[3,2-c]pyridin-1-yl)ethyl]-,
(3S)-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 209286-50-0

09/ 918,039

CMF C13 H16 N4 O


Absolute stereochemistry.



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 209286-82-8 CAPLUS

CN Carbamic acid, [(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209286-84-0 CAPLUS

CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 918,039



RN 209286-89-5 CAPLUS

CN Carbamic acid, [(3S)-1-[[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209286-91-9 CAPLUS

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209286-92-0 CAPLUS

CN 2-Naphthalenesulfonamide, N-[(3S)-1-[[5-chloro-1H-pyrrolo[3,2-b]pyridin-2-yl]methyl]-2-oxo-3-pyrrolidinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 918,039



=> d his

(FILE 'HOME' ENTERED AT 14:39:27 ON 19 SEP 2002)

FILE 'REGISTRY' ENTERED AT 14:39:33 ON 19 SEP 2002

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FUL
L4 11495 S PYRROLO AND PYRIDIN
L5 STRUCTURE UPLOADED
L6 50 S L5
L7 64 S L5 FUL SUB=L4

FILE 'CAPLUS' ENTERED AT 14:42:10 ON 19 SEP 2002

L8 7 S L7

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
31.52	321.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.34	-4.34

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:43:30 ON 19 SEP 2002